UnitedHealth Group Chief Accounting Officer Thomas E. Roos reported two tax-withholding share dispositions tied to equity compensation. On February 20, 2026, he surrendered a total of 326.067 shares of common stock in transactions coded “F” at $290.0000 per share to cover tax liabilities, leaving him with 28,999.418 shares of UnitedHealth common stock held directly.
ROOS THOMAS E reported disposition transactions in a Form 4 filing for UNH. The filing lists transactions totaling 322 shares at a weighted average price of $293.19 per share. Following the reported transactions, holdings were 29,325 shares.
Zaetta Christopher R reported disposition transactions in a Form 4 filing for UNH. The filing lists transactions totaling 213 shares at a weighted average price of $293.19 per share. Following the reported transactions, holdings were 10,115 shares.
McSweeney Erin reported disposition transactions in a Form 4 filing for UNH. The filing lists transactions totaling 153 shares at a weighted average price of $293.19 per share. Following the reported transactions, holdings were 11,040 shares.
UnitedHealth Group Chief Executive Officer, UHC, Timothy John Noel reported a tax-related share disposition under a Form 4. On 02/13/2026, 125.616 shares of UnitedHealth Group common stock were used to cover tax withholding at a price of $293.19 per share. Following this tax-withholding disposition, he directly owned 9,205.052 shares of common stock.
UnitedHealth Group executive Patrick H. Conway, Chief Executive Officer of Optum, reported a tax-related share disposition. On February 13, 2026, a Form 4 shows a code F tax-withholding disposition of 295.409 shares of UnitedHealth Group common stock at $293.19 per share. After this transaction, Conway directly beneficially owned 10,308.506 shares of common stock.
UnitedHealth Group Incorporated furnished a current report announcing that it has issued a press release with its fourth quarter and full year 2025 results. The press release is provided as Exhibit 99.1, and a hyperlinked PDF version is provided as Exhibit 99.2, both incorporated by reference in this report. The company also notes that the information under the results section is being furnished, not filed, so it is not automatically subject to certain liability provisions or incorporated into other securities law filings unless specifically referenced.
UnitedHealth Group Incorporated reports that its senior management team will meet with investors on January 12, 2026 and intends to reaffirm the company’s adjusted 2025 earnings per share expectations that were previously communicated on October 28, 2025. This indicates the company is currently standing by its earlier profit outlook for 2025.
The company also explains that its financial closing procedures for full-year 2025 are not yet complete, so actual results may change as closing activities, final adjustments, management review, and other developments occur. It cautions that final 2025 results could ultimately fall outside the previously discussed ranges, underscoring that this is a reaffirmation of expectations rather than a report of final earnings.
UnitedHealth Group director equity compensation reported
A Form 4 reports that director Paul R. Garcia received equity-based compensation from UnitedHealth Group Inc. (UNH) on 01/02/2026. The filing shows a grant of 168 deferred stock units at a price of $0, described as regular quarterly compensation for Board service. These deferred stock units are immediately vested but must be held until his Board service ends. The filing also shows a separate grant of 112 shares of common stock at $0, also as regular quarterly director compensation. Following these transactions, he beneficially owns UnitedHealth Group common stock directly and indirectly, including shares held through several trusts.
UnitedHealth Group director reports quarterly equity compensation grant
A UnitedHealth Group director reported receiving 285 shares of common stock on 01/02/2026 at a price of $0, reflecting a grant of deferred stock units as regular quarterly compensation for Board service. After this grant, the director beneficially owns 10,160 shares directly and 6,033 shares indirectly through a trust. The deferred stock units are immediately vested but must be held until the director’s service on the Board is completed.